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Abstract
Background: Polypharmacy is a national and local issue of concern within healthcare.
Deprescribing medications has been identified as a plausible solution for patients experiencing
polypharmacy. However, many healthcare providers are unaware of the practice of deprescribing
and, if aware, may not be implementing clinical tools for deprescribing effectively. The family
medicine clinical site supplies an opportunity for healthcare providers to utilize an evidencebased clinical tool to review medications, identify if inappropriate, and deprescribe if indicated.
Purpose: The purposes of the Doctor of Nursing Practice (DNP) project were to increase
deprescribing activity among prescribing healthcare providers and to increase prescribing
healthcare providers’ awareness and adherence to incorporating evidence-based clinical
guidelines for adults aged 62 years and older experiencing polypharmacy.
Methods: This quality assurance project involved educational sessions provided to prescribing
healthcare providers educating them how, when, and why to use the Medication Appropriateness
Index (MAI) clinical tool supplemented with handouts and clinical scenarios.
Results: Key results included statistically significant implications of deprescribing activity with
utilization of the MAI clinical tool (p=0.0003). Numerical increases were observed as
deprescribing activity increased. Notably, the average number of medications deprescribed was
1.85 medications.
Conclusion: This project underscored the importance of utilizing an evidence-based clinical tool
like the MAI clinical tool to increase the awareness of healthcare providers regarding
polypharmacy and increase the occurrence of deprescribing activity.
Keywords: polypharmacy, deprescribing, older adults
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Addressing Polypharmacy: Implementing the Medication Appropriateness Index Clinical
Tool to Increase Deprescribing by Healthcare Providers
Polypharmacy is a concerning issue in healthcare, affecting patients nationally and
locally alike. Polypharmacy is defined as the use of five or more medications on a regular basis
(Varghese et al., 2021). The potential for health complications and intra-drug interactions
increases as the number of medications taken increases (Tarn & Schwartz, 2020). The
concurrency of consumption of several medications in older adult patients is a serious problem in
pharmacotherapy (Hosseini et al., 2018).
Approximately 44% of men and 57% of women older than 65 years take five or more
nonprescription and/or prescription medications per week, and 12% of persons in this age group
take 10 or more nonprescription and/or prescription medications per week (Saljoughian, 2019).
Research has shown individuals older than 65 years of age constitute the largest group of
consumers of medications, and approximately 50% of this population utilizes at least one overthe-counter medication, and in addition, also consume at least one nutritional supplement
(Valenza et al., 2017).
Deprescribing medications has been identified as an intervention to combat
polypharmacy (Kurczewska-Michałek et al., 2021). Deprescribing is defined as the complex and
sensitive process of supervised withdrawal of excessive and inappropriate medications (Duncan
et al., 2017). Furthermore, deprescribing can be described as discontinuing, tapering, reducing
dose, or reducing frequency of a medication (Duncan et al., 2017). Professionals responsible for
the care of patients should be motivated to implement targeted polypharmacy interventions to
benefit those individuals who fall in these criteria (Kurczewska-Michałek et al., 2021).
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Background
Polypharmacy is a healthcare issue on the rise, as the older adult population continues to
age (Halli-Tierney et al., 2019). Polypharmacy poses a risk to patient health and safety, as well
as financial and cost related problems (Komiya et al., 2018). Taking multiple medications is
often burdensome on patients and can lead to drug interactions or adverse drug events (Komiya
et al., 2018). Rising healthcare costs and the price of pharmaceuticals is increasing the burden of
prices for patients and insurance companies (Khezrian et al., 2020).
At the present, an excess of 20,000 drugs are approved for use by the FDA to be used in
the United States (Tarn & Schwartz, 2020). Polypharmacy is on the rise in most of the
industrialized countries of the world and is a threat to overburden their already strained
healthcare systems (Tagny et al., 2020). Polypharmacy is a cause of significant concern in
relation to adverse health outcomes, higher use of medical care, and the increasing costs
associated with the excessive use of medications (Kardas et al., 2021).
Multi-drug use is increasingly prevalent in the older population (Badawy et al., 2020).
The occurrence of chronic diseases is increasing with age and the complication from these
diseases result in an increased use of medications among the older population (Hosseini et al.,
2018). Polypharmacy has been found to be the main risk for inappropriate prescribing of
medications, which has harmful effects on healthcare costs (Khezrian et al., 2020).
Health Risks
Polypharmacy carries health risks of liver and kidney damage, as most medications are
metabolized by the liver and then mostly excreted by the kidneys (Villén et al., 2020). This issue
increases the risk of drug-drug interactions and increases the likelihood of adverse drug events
(Villén et al., 2020).
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The implications on health risks of polypharmacy for the older population are significant
(Komiya et al., 2018). Several studies have been completed which examined the correlation
between polypharmacy and adverse outcomes (Chang et al., 2020). Aging places the older adults
at an increased risk for multi-morbidity and therefore in peril of the over-prescribing of
potentially harmful and inappropriate medications (Varghese et al., 2021). It has been found over
60% of Medicare beneficiaries have at least five chronic medical conditions (Unlu et al., 2020).
Polypharmacy in older adults has been associated with an increased occurrence of many
undesirable consequences, including a higher incidence of fall, frequency and length of in-patient
hospital stays, and mortality rate (Hosseini et al., 2018). Polypharmacy also has been found to
contribute to adverse drug events and geriatric syndromes (Gabauer, 2020). Additionally, the
presence of multiple, chronic conditions results in increased complexity of management of those
conditions, both for the patient and the provider (Mansoon et al., 2017).
This issue has been reported to result in adherence issues among older adults, especially
those not residing in nursing home facilities where medication administration is more closely
monitored (Saljoughian, 2019). The complexity of combinations of medications can cause the
beneficial aspects of individual medications to become detrimental when used in conjunction
with multiple other medications (Wastesson et al., 2018). Deprescribing therefore should be
considered as a potentially powerful intervention (Mach et al., 2021).
Concerns which correlated with adverse health risks for older adults included the use of
multiple medications resulting in mistakes in storage and self-administration, the diminished
effects of medications used in conjunction with other medications, and the serious possibility of
the negative effects of some medications on other comorbidities (Onder & Marengoni 2017).
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Studies of general surgery patients suggest polypharmacy is associated with a three to fourfold
increase in the likelihood of serious complications after surgery (McIsaac et al., 2018).
Health Benefits of Deprescribing
Many health benefits are related to deprescribing non-essential medications.
Deprescribing is a process of planned and monitored tapering of medications which are
potentially harmful or are no longer determined to be useful and appropriate as current therapy
(Salahudeen, 2018). Deprescribing has the potential to lessen some of the undesired outcomes
associated with polypharmacy (Duncan et al., 2017). When unnecessary or inappropriate
medications are discontinued, the medication load on the patient is reduced (Halli-Tierney et al.,
2019). Deprescribing one or more medications has the possible benefit of decreasing damage to
kidneys or liver (Villén et al., 2020).
Direct benefits of deprescribing include drug reactions, drug interactions, and
pharmaceutical costs may be reduced; moreover, quality of life may improve, and medication
adherence may be enhanced (Reeve et al., 2017). Deprescribing has also been discussed as a
promising intervention in events of organ morbidities, such as hepatic encephalopathy (Williams
et al., 2021).
Current Plans to Increase Deprescribing Activity
National plans to increase deprescribing activity include incorporating clinical tools into
everyday healthcare practice settings (Halli-Tierney et al., 2019). Many of these clinical tools are
being utilized, such as the Beers Criteria, the Medication Appropriateness Index, and the
Screening Tool for Older Peoples Prescriptions (Halli-Tierney et al., 2019). The MAI clinical
tool discussed in this project is presently being incorporated into healthcare practice and appears
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to be effective at identifying inappropriate medications to deprescribe (Halli-Tierney et al.,
2019).
The literature identifies several tools both historically and currently employed to assist
healthcare providers in efforts to deprescribe medications which are not beneficial or may cause
other harmful effects. The Beers Criteria, developed in 1991, is one of the more established tools
existing to help in the identification of potentially inappropriate medications in older adults
(Khamis et al., 2019). The STOPP (screening tool of older people’s prescriptions) and START
(screening tool to alert to right treatment) are also tools developed to assist in identifying
inappropriate medications (Halli-Tierney et al., 2019).
The MAI clinical tool is another tool to evaluate medication appropriateness, but is not as
solely geared toward older adults (Wastesson et al., 2018). The FORTA (Fit for the Aged) tool is
also an instrument designed to assist providers and classify medications into categories
addressing safety, efficacy, and age-appropriateness (Pazan & Wehling, 2020).
Healthcare Providers’ Use of Clinical Tools for Medication Review
Currently, healthcare providers overall are either underusing clinical tools for medication
review or are unaware of the significance of using clinical tools for medication review (HalliTierney et al., 2019). The issue of polypharmacy exists due to the practice of healthcare
providers not thoroughly reviewing and discontinuing medications when appropriate (HalliTierney et al., 2019). While pharmacists and nurses may play a role in polypharmacy, the most
important group of focus for intervention is the healthcare provider with prescriptive capabilities
(Halli-Tierney et al., 2019). Prescribing healthcare providers are in a unique position, as the
catalyst for prescribing and deprescribing medications (Halli-Tierney et al., 2019).
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Providers express difficulty exists with their ability to deprescribe (Farrell et al., 2017).
Reasons for underutilization of deprescribing include patient expectation, the time-consumption
of deprescribing, the medical culture, and organizational constraints surrounding the issue of
deprescribing (Wallis et al., 2017). Providers also cited patient resistance and unwillingness to
stop taking medications they are currently taking as one of the main barriers in deprescribing
(Reeve et al., 2017).
Physicians, pharmacists, and patients all share some responsibility for review and
evaluation of medications with the express concern of identifying any medications which can be
decreased or eliminated (Badawy et al., 2020). Providers should evaluate patient medications and
discuss with the patient those medications to be deprescribed (Halli-Tierney et al., 2019). Family
physicians are in a unique position to examine the issue of excessive or redundant medications or
those which no longer have a place in the patient's schedule of treatment (Schwartz, 2020).
Needs Analysis
The family medicine clinic is a clinic in a rural area. The area has a population of about
900 people; however, the clinic serves a population of about 4,000 patients. The clinical
preceptor is a physician at the family medicine clinic and will be overseeing this project. The
clinical preceptor likewise views polypharmacy as an issue in the current clinical practice and
voices a need for intervention. The clinical preceptor reported at least 50% of current patients at
the clinic have or are currently experiencing polypharmacy.
The Family Medicine Clinic
Current measures to address polypharmacy by utilizing the MAI clinical tool do not exist.
The family medicine clinic has no clinical tool for medication review at present. As previously
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stated, many patients at the clinic are experiencing polypharmacy and could benefit from
medications being deprescribed.
SWOT Analysis
A SWOT analysis (see Appendix A) was performed to determine existing internal
strengths and weaknesses and external opportunities and threats. Internal strengths were present
and included the family medicine clinic has a very dedicated and competent provider who has
experience in prescribing in older adult patients. While the provider is cognizant of the
implications of polypharmacy, the clinic lacks a procedure and monitoring tool to assist in
determining the extent of polypharmacy in patients and assist and direct in deprescribing of
identified medications. The provider would very willingly accept and utilize assistance and
direction to deprescribe when appropriate. Another strength of the MAI clinical tool is
availability and utility. Finally, the provider in the family medicine clinic was very supportive of
the DNP student and was eager to assist and learn how better to address polypharmacy in the
clinic patients.
The weaknesses included the general reluctance of patients to accept some medications
they have been prescribed and have taken for perhaps many years are no longer needed. This
perception was evident in the review of the literature and is cited in this manuscript. An
associated weakness is the time the provider at the family medicine clinic will need to devote to
the analysis of those medication lists. Consult with pharmacies will likely be needed to ensure a
complete, correct, and current list of medications is available. Then, extra time will be necessary
with patients to discuss the potential for the deprescribing of some of their medications. Also, the
provider will need to monitor those patients on a regular basis to talk with the patients about how
things are going with the lessened medication load.
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Opportunities existed regarding support for this project. With the successful
implementation of a deprescribing program, the patients at the family medicine clinic stand to
benefit from the removal of unneeded or redundant medications. This will result in a reduced
medicine load to adhere to at home. Additionally, the potential for the sharing of information
regarding polypharmacy and deprescribing is a considerable opportunity.
Threats to this project included the potential for the reluctance of patients to
deprescribing due to the belief the medications they have been taking for conceivably many
years are still needed. Another threat is the time commitments needed on the part of the provider
may prove to be excessive.
Problem Statement
The question addressed during this project is: “Among prescribing healthcare providers
(P), does implementing the Medication Appropriateness Index tool (I), compared to utilizing no
clinical tool (C), result in an increase in deprescribing activity (O)?”
Aims and Objectives
The overarching aims of this project were to:
•

Increase deprescribing activity among prescribing healthcare providers.
o Improve utilization of the Medication Appropriateness Index clinical tool when
reviewing patient medication lists and deprescribing.

•

Increase prescribing healthcare providers’ awareness and adherence to incorporating
evidence-based clinical guidelines for adults aged 62 years and older experiencing
polypharmacy.
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o Improve prescribing healthcare providers’ awareness and adherence regarding the
utilization and effectiveness of the Medication Appropriateness Index clinical
tool.
o To improve deprescribing activity related to polypharmacy as healthcare
providers review, prescribe, and deprescribe medications for patients.
Review of Literature
A review of literature was performed with priority placed on searches including the
topics of polypharmacy, deprescribing, and older adults. Search engines such as Cumulative
Index to Nursing and Allied Health Literature (CINAHL) and PubMed were utilized (see
Appendix B). Deprescribing, polypharmacy, and older adults were the key terms incorporated in
CINAHL searches. Likewise, deprescribing, polypharmacy, and older adults were utilized in
PubMed searches, as well. Reliable sources were gleaned by identifying peer-reviewed academic
journals within the last five years of publication.
Polypharmacy is an issue requiring much consideration among healthcare providers due
to its prevalence among the older adult patient population and the potential for benefits of
reducing medications and the potential serious consequences of not addressing medication load
among those patients. Polypharmacy increases the chance for a patient to receive a potentially
inappropriate medication (Niehoff, 2019). The current process for reviewing and identifying
potentially inappropriate medications contributing to polypharmacy is variable and widely
unstructured (Kurczewska-Michalak et al., 2021). By implementing a clinical tool to review
medications, a systematic approach can be created (Kurczewska-Michalak et al., 2021).
The average number of diseases in older adults is 7.7 per individual (Hosseini et al.,
2018). Having co-existing medical conditions often results in visiting several physicians and

10
specialists which may lead to various providers writing multiple prescriptions (Halli-Tierney et
al., 2019). The literature is clear regarding multimorbidity and the associated prescribing of
numerous medications is common in older adults (Mansoon et al., 2017).
When managing several chronic conditions in patients, multiple medications are often
necessary. Polypharmacy is most often observed in older patients with multiple comorbidities
(Zhang et al., 2021). The use of multiple medications increases the risk for drug-drug
interactions which may not exist when medications are taken alone (Varghese et al., 2021).
Malone (2021) found at times, polypharmacy issues are the result of incorrect medications being
prescribed.
Primary care physicians express several factors as hindrances to the deprescription of
medications among their patients (Halli-Tierney et al., 2019). Some of those hindrances to be a
lack of time, poor awareness of the harmful aspects of medications, fear of withdrawal reactions,
and patient resistance to ending some of their medications (Martin et al., 2018)
Intervention tools to assist providers in reduction or elimination of nonessential
medications do exist and have been employed and results reported in several publications.
Among these tools are several clearly established and validated methods for evaluation of
patients' medical regimen and identification of inappropriate medications (Niehoff, 2019).
Campins et al. (2017) utilized the STOPP Tool with over 503 providers and over 2700
drugs were evaluated. Approximately 26.5% of prescriptions were found to be potentially
inappropriate and 21.5% of those were changed, and the researchers reported significant
discontinuations, dose adjustments, and substitutions of medications in the intervention group
utilizing the STOPP tool (Campins et al., 2017).
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Martin et al. (2018) utilized the Beers Criteria in a study designed to determine if
implementation of the Beers would result in an increase in deprescribing between a control group
and intervention group of patients over 65 years of age. The conclusion was a significant
reduction in the intervention group, with approximately 42% of the intervention group seeing a
reduction in potentially inappropriate medications compared with approximately 12% in the
control group (Martin et al., 2018).
The MAI clinical tool is considered the most reliable and valid tool to measure
medication appropriateness (Krisch et al., 2020). This tool utilizes a precise medication review
using criteria set scrutinizing patient medications which have no benefit, have therapeutic
redundancy, and result in drug-drug or drug-disease interactions (Krisch et al., 2020). The MAI
clinical tool is evidence-based and has proven effectiveness to address the issue of polypharmacy
(Halli-Tierney et al., 2019).
The incorporation of the MAI clinical tool by healthcare providers on a routine basis
assists in the process of identifying inappropriate medications applicable for deprescribing
(Lopez-Rodriguez et al., 2020). Aside from simply utilizing a clinical tool to increase
deprescribing activity, clinical tools raise awareness for healthcare providers as reminders to
review medication lists at each visit and determine if all medications prescribed are necessary
and/or appropriate (Lopez-Rodriguez et al., 2020). Many healthcare providers are either unaware
of the issue of polypharmacy or are unsure of how to handle the problem (Lopez-Rodriguez et
al., 2020).
The consistent and ongoing monitoring of patients' current medication lists are necessary
to reduce medications taken and therefore any undesired interaction consequences (Halli-Tierney
et al., 2019). The literature revealed among older adults, intervention-centered techniques result

12
in greater deprescribing of inappropriate medications (Martin et al., 2018). The importance of
deprescribing is found consistently in the literature, and a review of the literature reveals
polypharmacy has significant negative consequences for both those individuals who take
medications which are redundant, excessive, or harmful, as well as the entire health care system
(Halli-Tierney et al., 2019).
To improve outcomes, clinical tools like the MAI need to be consistently implemented by
healthcare providers while reviewing medication lists. In addition, healthcare providers need to
have increased awareness of the issue of polypharmacy and increased adherence to medication
review tools (Halli-Tierney et al., 2019). Patients also need to be included in the medication
review process, as patient hesitancy may prove to be a barrier to procedure change (KurczewskaMichalak et al., 2021). Procedure changes regarding polypharmacy demand a change in attitude
and mind-set to improve outcomes and sustain success (Kurczewska-Michalak et al., 2021).
Theoretical Model
The theory utilized to guide this project is Lewin’s Theory of Planned Change. Kurt
Lewin published a Three-Step Model of Change which has become the most influential approach
to organizational change (Burnes, 2019). Lock (2018) explains Lewin’s Model proposed three
main stages to move from a current state through a change process to a desired future state;
thereby, utilizing the three stages: unfreezing (assess why change is needed), change (movement
toward the desired state), and refreezing (set the new behavior as the new normal).
This theory will assist the progress of this project by allowing certain behaviors to occur.
First, in unfreezing, the provider will recognize the problem of polypharmacy and consider why
deprescribing needs to occur. This will occur as the provider is given access to the literature on
polypharmacy and understands the implications of deprescribing medications. Secondly, the
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change component will be enacted by enabling the provider to change beliefs and procedures;
furthermore, allowing implementation of a program of review of medication lists of patients and
have a mechanism to allow deprescribing to occur. Thirdly, in the refreeze stage, the provider
will move forward with the new behavior intact, encouraging deprescribing to proceed in a
methodical manner (Lock, 2018).
Methodology
This project anticipates improving deprescribing activity and awareness by healthcare
providers. Specifically, this project will utilize the Lewin Model to allow the provider to proceed
from a difficult task to a manageable task which can be successfully implemented.
The primary intervention of this project is to equip the provider with the ability to
increase deprescribing among patients. In the first stage, the provider will be presented with the
pertinent information and will be allowed to process and provide thoughts on their current beliefs
and actions in relation to the status of if and how polypharmacy is approached at the present
time. In the second phase of change, the MAI clinical tool will be introduced and employed. In
the final phase of unfreezing, the provider will proceed to utilize the MAI clinical tool in an ongoing and consistent manner to review medication lists, identify potentially inappropriate
medications, and deprescribe those medications.
After implementation of the project intervention, it will be possible to evaluate and
analyze how effectively the provider utilized the MAI clinical tool to successfully deprescribe
unnecessary medications for the twenty selected patients.
Setting
The setting where this project was conducted involved a family medical clinic located in
the rural, Southeastern region. The family medicine clinic was staffed with one medical doctor.
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The average number of patients seen on a typical full workday is twenty-five patients. Of those
patients, approximately fifteen per day would be above age 62, and typically those patients aged
62 and older had several medical conditions treated with multiple medications.
Population
The population of interest was the healthcare provider with prescriptive capabilities at the
family medicine clinic. Nurses and clinical staff also working at the family medicine clinic were
excluded from this project
Inclusion/Exclusion Criteria for Healthcare Providers
The inclusion criteria were as follows:
•

healthcare providers with prescriptive capabilities

•

working within clinical site facility

•

employment status: full-time

The exclusion criteria are listed below:
•

healthcare providers caring for vulnerable patient populations like cancer patients

•

healthcare providers without prescriptive capabilities

Recruitment
A flyer for recruitment purposes was prepared and sent to the healthcare provider at the
family medical clinic (see Appendix C). The flyer allowed the participating provider time for
review and consideration. The clinical preceptor was the sole participant in the project
population. A meeting was arranged, and the provider was able to ask questions and give consent
to participate.
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Consent
Consent was collected from the project participant voluntarily prior to project
intervention implementation (see Appendix D). Participants were informed this project would be
led by the Principal Investigator (PI), but university faculty could be contacted at any time during
the project implementation. The PI of this project did not have any impact over administrative
decisions at the family medicine clinic. Any data collected by the PI would be non-identifiable
and confidentiality of all participants would be maintained (see Appendix D) for plan of
confidentiality).
Design
This quality assurance project utilized the MAI clinical tool to allow the healthcare
provider at the family medicine clinic to assess medicine lists of patients and identify
inappropriately prescribed medications. An educational session was provided for the healthcare
provider at the family medicine clinic (see Appendix E). The identification of those medications
would then allow the provider to deprescribe unnecessary medications during primary care visits.
The provider at the family medicine clinic received the MAI clinical tool hard copy version (see
Appendix F) and access to electronic version to be utilized during the primary care visits. The
DNP PI contacted the MAI clinical tool’s creator, Dr. Joseph Hanlon, via email and asked
permission to use the tool in DNP project. The DNP PI was informed by Dr. Hanlon the MAI
clinical tool is public domain and does not require permission to use (see Appendix F).
After identification of the twenty patients, a consultation was conducted with the provider
and the DNP PI. At the meeting, the DNP PI reviewed the twenty patients and the medications
currently being taken by each of the patients. The provider and the DNP PI identified those
medications to most likely be deprescribed. The provider noted those medications on the chart to
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be discussed with the patient at their next scheduled visit. At the next scheduled visit, the
provider discussed with each of the patients any medications eligible for elimination, and the
patients were allowed to agree or disagree with any changes to their medication regimen. Any
medications deprescribed were noted on the chart, and the provider also kept a hand-written
record of any eliminated medications.
After the twenty patients were seen during their scheduled office visit, medications were
either deprescribed or not. Of course, the number of patients experiencing polypharmacy was the
original twenty patients; however, only a certain number of those patients had potential
medications to be deprescribed. The provider and the DNP PI evaluated components such as
average number of medications deprescribed, average patient age, demographic information
based on gender, and the average number of medications a patient was initially taking.
Chart Review
A pre-intervention chart review with the provider and DNP PI was conducted after IRB
approval was obtained. The chart review allowed the provider and the DNP PI to identify those
patients aged 62 and older who were taking five or more medications. Medication lists for those
identified patients were available and the number of medications for each of the identified
patients was determined. The medications included all types of medications, including over-thecounter medications, vitamins and supplements, as well as those prescribed by providers. The
provider, acting as preceptor, was the only individual able to access identifiable patient
information, such as name, date of birth, or medical record numbers. This information was deidentified before reviewed by the DNP PI.
During the chart review, any medications deemed as candidates for deprescription were
identified and noted by the provider in the chart for discussion at the next scheduled visit of each
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patient. After the chart review was completed, twenty patients aged 62 and older who were
taking at least five medications were identified. These twenty patients were all previously
scheduled for an office visit in the coming weeks, so this provided certainty the designated
patients could be evaluated in a short timeframe.
Risks and Benefits
No physical harm will affect participants in this project. The only risk of harm would
pertain to confidentiality of patients, and such risks were mitigated by ensuring no names or
identifiable information were associated with any patients. When medications lists were
presented to the DNP PI, patient names and demographic information were not viewed in any
way, and the patients were only identified by alphabetical letters assigned by the family medicine
clinic provider. At no time was the DNP project leader privy to any patient names or information
other than their medication lists and age range (older than 62 years of age).
Benefits of this project included equipping providers at the family medicine clinic with a
tool to assist them in the deprescribing of unnecessary medications for their patients. Benefits
also extended to patients as the deprescribing of unnecessary medications will likely have
various positive results.
Compensation
No version of compensation was offered or provided during this DNP project to any
participants, other than educational handouts and information.
Timeline
The timeline is included in Appendix G. The timeline developed for the implementation
and completion of this project was nine weeks. The projected dates were January 14, 2022, to
March 18, 2022. Prior to the beginning of the implementation, the DNP project leader worked
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with faculty to obtain proper guidance and permission to continue with the project. In December
2021, the Institutional Review Board of Jacksonville State University approved the project (see
Appendix M). The DNP PI also completed CITI training in 2021 prior to project implementation
(see Appendix L).
Budgets and Resources
A budget was prepared prior to project implementation. The project actual cost was less
than the anticipated cost. Finances for this project proved to be reasonable and low cost.
Finances primarily involved copies of educational materials (see Appendix H).
Evaluation Plan
Statistical Considerations
The data collection tool was developed by the DNP PI in a handwritten deprescribing log
template (see Appendix I). The tool was used to collect medication information from each of the
patients aged 62 and older who received primary care at the family medicine clinic. The
statistical collection of data from the study involved review of charts of patients aged 62 and
older and who in addition take five or more medications.
The general information for each patient was presented in table form and included
gender, age, and number of medications taken. The provider was then educated regarding how to
utilize the MAI clinical tool to perform deprescribing nonessential medications. The provider
then proceeded to implement the tool with each of the twenty patients at their scheduled primary
care visit.
Post-intervention data included the number of patients taking five or more medications.
In addition, data was compiled to evaluate how many patients had medications deprescribed
versus how many did not. Other post-intervention data included the average number of
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medications per patient, the average number of medications deprescribed per patient, and the
average age of patients participating in the patient population pool.
For statistical analysis, a paired t-test was used to compare the number of medications
each patient was taking before the intervention with the number of medications after the
intervention. The paired t-test enables the determination of a statistically significant difference
between two groups' (the same patients being compared pre-intervention and post-intervention)
medication amounts both before and after intervention. A significance level of a < 0.05 was
established when performing the t-test. The p- value results from the t-test were compared to the
a = 0.05 established significance level to find the degree of statistical significance.
Pearson correlation values from the paired t-tests were utilized to allow further analysis
of the potential reduction in medication load for each of the sample patients. These statistical
analyses allowed a determination to be made as to whether there existed a significant difference
between pre-intervention and post-intervention.
Data Maintenance and Security
The only information the DNP project leader was privy to in regard to patient
demographics was gender, age, medical conditions, and medication lists. At no time was any
patient confidential information provided to the DNP project leader. Also, the exact location of
the confidential information at the family medicine clinic was not disclosed to any parties other
than the clinical preceptor and the PI.
Results
The project tracked the twenty patients at the family medicine clinic meeting the
following criteria: aged 62 years and older and prescribed five or more medications. The
provider at the clinic utilized the MAI clinical tool to evaluate the medication lists of each of the

20
twenty patients. At the next visit of each of the patients, the provider discussed medications
deemed inappropriate and discussed the option of elimination by deprescribing. After each of the
patients were seen, the number of starting medications before deprescribing were compared with
the new total number of medications after any deprescribing of medications occurred.
Pre-intervention, all of the twenty patients were taking five or more medications (100%)
and were candidates for deprescribing. The results of the project indicated out of the twenty
patients, seventeen (85%) were found to have inappropriate medications indicating deprescribing
or discontinuing. It was determined after employing the tool, the other three patients (15%) did
not have any medications with the potential to be eliminated. In the case of the seventeen
patients with inappropriate medications, all of the seventeen agreed to the elimination of at least
one medication, if not more.
Pre-intervention, the average number of medications per patient was 12.25. Postintervention, the average number of medications per patient was 10.4. The average number of
medications deprescribed was 1.85 medications. The medication class most likely to be
deprescribed appeared to be antihistamines. Significant to remark, the provider did not write any
new prescriptions during any of the visits, so no medications were added to the medication load
of each patient. Notably, with many patients, polypharmacy continued to be present, even despite
positive deprescribing activity. For example, a patient was taking twelve medications and had
two medications deprescribed, leaving the patient with a total of ten current medications;
therefore, deprescribing activity occurred but the patient was still experiencing polypharmacy.
Results of Chart Review
The chart review resulted in a total of twenty patients who were identified as being age
62 years or older and currently prescribed five or more medications. The chart review found the
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average age of the patients was 74.95 years of age. The sex/gender of the patients was fairly
equal, including eleven males and nine females. The average number of medications taken by the
group was 12.25. Each of the twenty patients were scheduled to come for an office visit during
the indicated weeks of implementation.
The analyzed p-value was 0.0003, which is less than 0.05. Since the p-value was less than
0.05, the results were statistically significant. From analysis utilizing the paired t test, the
following data was ascertained. The mean of the two groups was 1.85. The standard deviation
was 1.7965 and t = 4.4886. Utilizing the Pearson Correlation Coefficient determined r was equal
to 0.8996.
Results of Survey Responses
A tool was constructed by the DNP project leader to allow an evaluation of the attitudes
of the healthcare provider regarding polypharmacy. A pre-intervention questionnaire (see
Appendix J) was administered to the provider prior to any presentation of education regarding
polypharmacy. The provider was then educated on the pertinent aspects of polypharmacy and
was introduced to the MAI clinical tool.
Then, the intervention with the patients occurred over the next five weeks. After all the
patients were seen at their regular scheduled visits, the DNP PI then returned to the clinic to meet
with the provider. At that time, a post-intervention questionnaire (see Appendix K) was
administered measuring the attitudes of the provider concerning polypharmacy. The comparison
of the pre-intervention questionnaire with the post-intervention questionnaire allowed the DNP
PI to draw conclusions regarding the attitudes of the provider pre-intervention and postintervention.
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The convenience sample was extremely limited for this project. The population of
interest consisted of one healthcare provider with prescriptive capabilities. Therefore, no
alternative participants exist to compare results across the population of interest. However, the
individual healthcare provider’s responses to the questionnaires can be formulated and analyzed
in data collection.
Questions eight, nine, and ten of the pre-intervention questionnaire evaluated the
healthcare provider’s knowledge regarding the MAI. The healthcare provider did successfully
answer all three questions correctly (100%), even despite knowing very little about the MAI
clinical tool. To note, the pre-intervention questionnaire was administered prior to the
educational session.
Questions five, six, seven, eight, and ten on the post-intervention questionnaire were
graded with responses ranging from never to always, with question ten ranging from strongly
unprepared to strongly prepared. The healthcare provider did not find the MAI clinical tool to be
convenient to use, nor did the healthcare provider find the MAI clinical tool to be essential to the
medication review process. The healthcare provider did respond “usually” to question six and
seven regarding how often inappropriate medications were identified and how often did
deprescribing occur. The healthcare provider answered question ten regarding personal
preparedness to use the MAI when reviewing medications to deprescribe as “strongly prepared”.
Discussion
This project aimed to address the concerning issue of polypharmacy affecting many older
adult patients in primary care settings. The results of the project provided promising findings and
supported the assumption suggesting primary care providers can evaluate patient medication lists
and identify medications to be deprescribed or discontinued. Further supporting evidence
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indicated patients with unnecessary medications were willing to allow deprescribing of such
medications. The results of the project confirmed the views expressed in the literature review
suggesting polypharmacy can be addressed via education and access to an appropriate
medication review tool.
The main aims of the project were to increase deprescribing activity among prescribing
healthcare providers and increase prescribing healthcare providers’ awareness and adherence to
incorporating evidence-based clinical guidelines to address polypharmacy. Significant findings
of this project included statistically significant results of deprescribing activity with utilization of
the MAI clinical tool (p=0.0003). Numerical increases were observed as deprescribing activity
increased. Notably, the average number of medications deprescribed was 1.85 medications.
The awareness of the healthcare provider increased as a result of project implementation. The
healthcare provider was surprised by how many medications patients were being prescribed;
even more so, concern existed regarding the number of medications considered to be
inappropriate or unnecessary. The healthcare provider concluded the project’s target population
are the prime candidates to be leaders in the process of addressing polypharmacy by means of
deprescribing medications.
While the healthcare provider supported the incorporation of the MAI clinical tool as a
guide and reminder to review medications for appropriateness, the healthcare provider
communicated the tool was cumbersome to use at times. The MAI clinical tool is considered an
implicit tool and is proven to be more time consuming than other clinical tools (Halli-Tierney et
al., 2019). The MAI clinical tool focuses more on physician judgment and being patient-centered
(Halli-Tierney et al., 2019). Yet, since the tool is more patient-centered, patients are more likely
to be agreeable with the deprescribing of medications (Halli-Tierney et al., 2019). This
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component of patient compliance was observed by the healthcare provider, as each patient who
was offered medication deprescribing was receptive.
Implications for Clinical Practice
The project’s aims regarding clinical practice were met evidenced by an increase in
deprescribing activity and an increase in healthcare providers’ awareness of the issue of
polypharmacy. The project revealed useful findings for clinical practice. Among these is the
clear conclusion regarding the excessive number of patients in a primary care clinic being
prescribed multiple medications.
Furthermore, patients can successfully experience medication deprescribing of at least
some of the unnecessary medications. Another implication is providers can manage the
additional time commitment for evaluation of patient medication lists to identify potentially
inappropriate medications. Also implied is the concept of the reliability and success of the MAI
clinical tool to utilize to determine the necessity of medications.
Implications for Healthcare Policy
The results of the project indicate healthcare clinical management or individual
healthcare clinics can implement the evaluation of patient medications as a requirement for
prescribing providers. Furthermore, healthcare policy leaders can determine evidence-based
clinical tools are reliable to ascertain which medications can be removed regularly and
consistently. In addition, healthcare policy leaders could include the requirement for prescribing
healthcare providers to discuss medication lists with patients at least annually and initiate
discussion regarding the necessity of each of the medication.
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Implications for Quality/Safety
The project utilized the MAI clinical tool to allow providers to evaluate the medication
load of patients and determine if any medications can be eliminated. When medications are
determined to be inappropriate, those can be discussed with patients with the intention of
eliminating those medications. When medications are eliminated, patients will benefit
financially; additionally, drug-drug and drug-disease interactions will be reduced (Halli-Tierney
et al., 2019).
Medication safety is a major topic in healthcare today, as patient age continues to
increase and co-morbidities continue to accumulate (Halli-Tierney et al., 2019). Polypharmacy is
a threat to medication safety, as negative consequences may materialize when patients are taking
multiple medications (Halli-Tierney et al., 2019). Addressing polypharmacy focuses on quality
and safety issues such as decreasing patient falls and increasing quality of life (Halli-Tierney et
al., 2019).
Implications for Education
The result of this project indicates providers can be educated in relation to deprescribing
medications for their patients. Patients can also be successfully educated in relation to the
benefits of deprescribing. Education appears to be positively welcomed and accepted by
healthcare providers and patients alike. Not only increasing education distribution, but increasing
education frequency, can further reinforce the awareness of polypharmacy and the adherence to
utilizing clinical tools to assist with medication review and identifying inappropriate
medications.
Primary care clinic sites should consider at least annual educational sessions regarding
polypharmacy and deprescribing medications. The education can be offered via clinical in-
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service sessions and can also be administered to new employees during orientation. Educational
sessions should be instructive and open for discussion and questions to facilitate the best learning
environment.
Limitations
Three main limitations of this project exist. The first limitation was the limited number of
participating providers. One provider at the family medicine clinic participated. The participating
healthcare provider was the lead provider at the clinic and thereby does hold considerable
influence over the other providers at the clinic. However, the other healthcare providers did not
participate in the project implementation.
The other limitation was the small sample size. Twenty patients were included in the
population pool of patients. These patients’ medication lists were evaluated, and the participating
healthcare provider attempted, during the intervention, to deprescribe medications. Time
constraints, namely the short implementation timeframe, also contributed as a limitation since
less patients were able to be seen. In addition, time constraints existed for the healthcare provider
attempting to use the MAI during patient office visits to review extensive medication lists,
identify potentially inappropriate medications, and then initiate the process of deprescribing.
Dissemination
The findings for this research will be shared at the Jacksonville State University Annual
Virtual Dissemination Day on July 15, 2022. The findings will be disseminated via poster
presentation or podium presentation, as well as within this manuscript. The results were shared
with the clinical preceptor in person at the conclusion of project implementation.
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Sustainability
The family medicine clinical site will continue to have the option to utilize the MAI
clinical tool in practice. This project can easily be implemented again in a clinical setting with
patients or in a pharmaceutical setting with pharmacists. In addition, the project can be
implemented by nursing staff during the triage process, new patient process, or medication
reconciliation process.
Not to mention, various other tools exist for medication review and to assist with
deprescribing medications. This DNP PI will carry on the practice after graduating. This DNP PI
already considers using the MAI to assess medication necessity for patients. This DNP PI is
eager to deprescribe medications when possible and include patients in the decision-making
process.
This DNP PI’s plan for sustainability involves leaving the participating healthcare
providers with copies of the MAI clinical tool for future use to review medication lists. The MAI
essentially provides a check-list for healthcare providers to use in determining medication
necessity. Collaborating with patients will be a great future endeavor; furthermore, receiving
feedback from patients regarding their feelings about polypharmacy and deprescribing will aide
in sustainability.
This DNP project leader will carry on the practice in her employment as a family nurse
practitioner. This DNP project leader is eager to evaluate medication lists for those in her care
and is excited about being able to potentially help in the elimination of unnecessary medications
in her patients. The process of including patients in the decision-making process is also very
desirable to this DNP PI.
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Plans for Future Scholarship
This project proved to be helpful to further confirm existing data surrounding the topics
of polypharmacy and deprescribing. However, further research will be needed in the future to
continue support and progress towards the reduction of unnecessary medications. Further studies
to utilize different clinical tools for medication review will be informative. Moreover, future
studies regarding patient participation will address the barriers of patient hesitancy regarding
discontinuing medications.
This project was led by one DNP PI and involved the participation of one prescribing
healthcare provider. Future scholarship would benefit from including more prescribing
healthcare providers in the study, as well as a mix of disciplines, such as nurse practitioners and
physician assistants. In addition, such studies may benefit from including pharmacy staff in the
intervention, since pharmacists hold the prime responsibility of dispensing prescribed
medications. Consequently, this project involved a small group of twenty patients evaluated over
an approximately five-week timeframe. Future studies would be more helpful if evaluating a
larger group of patients over a longer timeframe. In addition, patient follow-up after
deprescribing medications would be assistive to such project topics.
Throughout the formulation and implementation of this project, the DNP PI was
optimistic this project would yield results to prove beneficial to the professional field. The DNP
project leader has also been encouraged and has gained confidence future research can be
conducted and may yield information to assist the professional community.
Conclusion
Polypharmacy remains a concerning issue nationally and locally, and utilizing clinical
tools, like the MAI clinical tool, remains a viable solution to the issue (Saljoughian, 2019). The
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MAI assists prescribing healthcare providers to review, analyze, and identify if medications are
inappropriate and can be discontinued (Halli-Tierney et al., 2019).
Despite evidence-based research and studies, a need still exists for more effective
methods of reviewing medications and identifying inappropriate medications (Halli-Tierney et
al., 2019). This DNP project was aimed towards increasing deprescribing activity and reducing
polypharmacy, while raising awareness of the issue of polypharmacy in primary care practice
settings. This DNP project aspired to increase awareness and adherence of prescribing healthcare
providers to the incorporation of evidence-based clinical guidelines and clinical tool to address
polypharmacy.
To continue to increase awareness and implementation of evidence-based clinical
guideline tools, further research should focus on determine barriers impeding compliance over a
lengthened timeframe. Determining barriers to deprescribing among healthcare providers and
patients alike will be helpful to increase acceptance and adherence with deprescribing activity.
Utilizing the MAI has a strong correlation with the ability of healthcare providers to
deprescribe medications, so more education and counseling should be directed toward
prescribing healthcare providers. Projects, such as this one completed by the DNP PI, highlight
the benefits of implementing clinical tools for the process of medication review to identify
inappropriate medications and deprescribe when indicated.
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Tables
Table 1
Demographics and Medication Load
Characteristics

Frequency

Percentage

Male
Female

11/20
9/20

55%
45%

Experiencing polypharmacy

20/20

100%

Aged 62-70
Aged 71-80
Aged over 81

6/20
9/20
5/20

30%
45%
25%

Taking 5-9 medications
Taking 10-14 medications
Taking 15 or more
medications

5/20
11/20
4/20

25%
55%
20%
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Table 2
Chart Review Pre-intervention and Post-intervention
Polypharmacy
occurrence

Pre-intervention
frequency

Post-intervention
frequency

p-value

Medications
prescribed

12.25

10.4

0.0003
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Appendix A
SWOT Analysis: Family Medicine Clinic
Internal

External

Strengths

Weaknesses

Opportunities

Threats

-The family medicine
clinic has a very
dedicated and
competent provider
who has experience in
prescribing in elderly
patients.
-The provider would
very willingly accept
and utilize assistance
and direction to
deprescribe when
appropriate.
-The Medication
Appropriateness Index
(MAI) clinical tool is
available and not
difficult to utilize. The provider in the
family medicine clinic
is very supportive of
the DNP student and is
very eager to assist.

-The general reluctance
of patients to accept
some medications they
have been prescribed
and have taken for
perhaps many years are
no longer needed.
-The time the provider at
the family medicine
clinic will need to
devote to the analysis of
those medication lists.
-Consult with
pharmacies will likely
be needed to ensure a
complete, correct, and
current list of
medications is available.
-Extra time will be
necessary with patients
to discuss the potential
for the deprescribing of
some of their
medications.

-The patients at the
family medicine
clinic stand to benefit
from the removal of
unneeded or
redundant
medications.
-Result in a reduced
medicine load to
adhere to at home.
-The potential for the
sharing of
information regarding
polypharmacy and
deprescribing is a
considerable
opportunity.

-The potential
for the reluctance
of patients to
deprescribing
due to the belief
the medications
they have been
taking for
conceivably
many years are
still needed.
-The time
commitments
needed on the
part of the
provider may
prove to be
excessive.
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Appendix B
Table of Evidence: Polypharmacy among adults aged 62 years and older
Clinical Question: Among prescribing healthcare providers (P), does implementing the Medication Appropriateness
Index tool (I) compared to utilizing no clinical tool (C) result in an increase in deprescribing activity (O) over a nineweek timeframe (T)?
Article

Author & Date

Evidence Type

Sample, sample size, setting

Study findings related
to PICOt question

Limitations

1

Niehoff, K.,
Mecca, M., &
Fried, T.
(2019).

Narrative review

Database: PubMed.

-Polypharmacy can
cause adverse
outcome.

-Concluded more
data is required.

-Criteria-based drug
reviews are
recommended.

-“Gold standard”
criteria was not
identified.

-Polypharmacy should
be addressed more
seriously.

-Long lists of
medications
reviewed.

2

3

Keywords: medication
appropriateness; multimorbidity; polypharmacy.

KurczewskaMichalak, M.,
Lewek, P.,
JankowskaPolańska, B.,
Giardini, A.,
Granata, N.,
Maffoni, M.,
Costa, E.,
Midão, L., &
Kardas, P.
(2021).

Scoping review

Hosseini, S.,
Zabihi, A.,
Amiri, S., &

Descriptive/analytical
cross-sectional study

13 articles of criteria to
evaluate appropriateness.
Database: CINAHL,
EMBASE, PubMed.
Keywords: adverse drug
event; adverse drug reaction;
elderly; explicit criteria;
inappropriate prescribing;
multimorbidity; older adults;
polypharmacy.
Timeframe: January 2010March 2018.
1616 individuals, ages 60
years and older. 883 men,
733 women.

-Little data
supporting
-Medication
appropriateness should criteria.
be evaluated.

Evidence
Level and
Quality
Level IV,
Quality
C.

Level III,
Quality
C.

-49 papers
identified.
-Polypharmacy is
more prevalent in
older women.

-one location.

Level II,
Quality
A.
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Bijani, A.
(2018).

4

Halli-Tierney,
A., Scarbrough,
C., & Carroll,
D. (2019).

Setting: city of Amirkola in
northern part of Iran.

Compilation. The search
included RCT, clinical
trials, reviews, metaanalyses, case reports,
evidence-based
guidelines.

Databases: PubMed,
Cochrane Database of
Systematic Reviews,
UpToDate, the Canadian
Task Force on Preventive
Health Care, the ABIM
Foundation’s Choosing
Wisely website, the Centers
for Disease Control and
Prevention guideline on
prescribing opioids for
chronic pain, the U.S.
Preventative Services Task
Force recommendations.
Keywords: polypharmacy,
multiple medications, risks,
potentially inappropriate
medications, deprescribing.

-Polypharmacy is a
serious issue requiring
intervention.
-Educational programs
are a reasonable
approach to inform
physicians, pharmacy
staff, and healthcare
staff about medication
safety and
polypharmacy.
-Patients and
physicians may be
cautious to the
practice of
deprescribing.
-Validated tools exist
to address
polypharmacy.
-The MAI clinical tool
is a patient-centered
tool to utilize to
evaluate medication
necessity.

-Small sample
size.

-Short timeframe.

Level I,
Quality
A.
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5

Masnoon, N.,
Shakib, S.,
Kalisch-Ellett,
L., & Caughey,
G. (2017).

Systematic review

Timeframe: July and August
2018, February 2019.
Databases: Preferred
Reporting Items for
Systematic Reviews and
Meta Analyses (PRISMA)
checklist, MEDLINE (Ovid),
EMBASE, Cochrane.
Timeframe: January 2000May 2016.

6

Zhang, S.,
Swallow, N.,
Pomilla, W.
(2021).

Opinion of recognized
expert

Not applicable.

-Most commonly used
definition for
polypharmacy is five
or more medications
daily.
-Tools or criteria, like
the MAI clinical tool,
can be used to identify
potentially
inappropriate
medications.
-Addressing
polypharmacy and
reviewing medications
requires a holistic
approach to medical
care.
-Risk factors for
polypharmacy include
age, sex, chronic
conditions.
-Deprescribing is a
proposed intervention
for polypharmacy and
the MAI clinical tool
is a recommended
guideline.

-Studies in
English only were
used.

Level 1,
Quality
A.

-possible
information bias.
-only articles
from 2000 to
present (2016)
were used.

-No setting or
sample size
included.
-Expert opinion
only.

Level V,
Quality
D.

42
7

Varghese, D.,
Ishida, C., &
Hayas, H.
(2021).

Continuing education
activity

Not applicable.

-Older adults often
require multiple
medications to
manage comorbidities.
-Adverse drug events
are a risk of
polypharmacy.

8

9

Malone, L.
(2021).

Martin, P.,
Tamblyn, R.,
Benedetti, A.,
Ahmed, S., &
Tannenbaum,
C. (2018).

Opinion of recognized
expert

Randomized clinical trial

Not applicable.

Setting: community
pharmacies in Quebec,
Canada.
Timeframe: February 2014September 2017, with followup until February 2018.

-Strategies, like using
clinical tools, can be
implemented to
prevent
polypharmacy.
-Identifying
inappropriate
medications and
deprescribing can
improve patient
outcomes.
-Annual wellness
visits are a reasonable
time to recognize and
address
polypharmacy.
-Inappropriate
medications exist with
older adults at an
alarming rate.
-Deprescribing or
discontinuing

-No setting or
sample size
included.

Level V,
Quality
D.

-Educational use
only.

-No setting or
sample size
included.

Level V,
Quality
D.

-Expert opinion
only. No
references cited.

-Small sample
size.
-one location.

Level I,
Quality
A.
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Sample Size: 248 patients
and 241 to control group.

10

Campins, L.,
Serra-Prat, M.,
Gozalo, Lopez,
D., Palomera,
E., Clara, A., &
Cabre, M.
(2017).

Randomized controlled
trial

Setting: Primary care centers.
Sample: polymedicated
elderly people (aged 70 years
and older).
Sample size: 503 patients.
2709 drugs evaluated.

medications is a
reasonable
intervention to address
polypharmacy.
-Sedative-hypnotics,
first-generation
antihistamines,
glyburide, or nonsteroidal antiinflammatory drugs
are over-prescribed
and often
inappropriate with
older adults.
-Medication
evaluation programs
are helpful to address
polypharmacy and
reduce potentially
inappropriate
medications.
-Reducing potentially
inappropriate
medications is a safe,
evidence-based
intervention to address
polypharmacy.
-Continued reevaluation and followup of medication lists
is needful to

-no differences
observed in
reduction rates of
hospitalizations or
death among
elderly patients.

Level 1,
Quality
A.
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11

12

Krisch, L.,
Mahlknecht, A.,
Bauer, U.,
Nestler, N.,
Hempel, G.,
Osterbrink, J.,
& Flamm, M.
(2020).

Content-based approach

LopezRodriguez, J.A.,
Rogero-Blanco,
E., AzaPascualSalcedo, M.,
Lopez-Verde,
F., PicoSoler, V., &
LeivaFernandez, F.
(2020).

Cross-sectional study

Not applicable.

Sample: 593 communitydwelling elderly aged 65-74
years.
Size: A total of 4,386
prescriptions were evaluated.
Setting: Spanish regions
(Andalucia, Aragon, Madrid).

emphasize and sustain
the effects of
deprescribing.
-The MAI clinical tool
is recommended as the
most reliable, implicit
tool to evaluate
medication
appropriateness.
-The MAI clinical tool
can be correlated to
the mean reduction of
medications.
-The MAI clinical tool
scores increase when
new medications are
added.
-Explicit and implicit
criteria tools are
indicated for use when
addressing
polypharmacy by
identifying
inappropriate
medications.
-The MAI clinical tool
recognizes greater
medication
inappropriateness than
other explicit criteria
tools.

-content-based.
-No setting or
sample size
included.

-Addressed an
objective against
initial design.
-Possible
inappropriate
valuation.

Evidence
V,
Quality
D.

Level II,
Quality
B.
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Appendix C
Participant Recruitment Flyer
DNP Nursing Project in Need of Participants!

PURPOSE: Educate healthcare providers to utilize the Medication Appropriateness Index
clinical tool to increase deprescribing activity and reduce the prevalence of polypharmacy
among patients aged 62 years and older.
____________________________________________________________________________
WHO: Healthcare providers at clinical facility site with prescriptive capabilities *Note:
Participation is voluntary and can be withdrawn at any time.
____________________________________________________________________________
WHAT: Attend 30-minute one-time educational session to learn about polypharmacy,
deprescribing, and the Medication Appropriateness Index clinical tool.
____________________________________________________________________________
WHERE: On site at clinical facility location.
____________________________________________________________________________
WHEN: 30-minute educational session in January during the day when office is closed for
lunch.
____________________________________________________________________________
DATE: To be determined and announced at later time.
If interested in participation, please contact:
Lori K. Floyd, MSN, CRNP, FNP-C at
lgorham@stu.jsu.edu or phone number can be provided.
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Appendix D
Participant Consent Form
TITLE OF STUDY: Addressing Polypharmacy: Implementing the Medication Appropriateness
Index clinical tool to Increase Deprescribing by Healthcare Providers.
Principal Investigator: Lori K. Floyd, MSN, CRNP, FNP-C

This consent form relates to an informed consent process for a Doctor of Nursing Practice (DNP)
student project, and it will supply you with information to assist you in deciding whether or not
you are interested in participating in this project. This consent form is designed to inform you
what the project is about and what will occur during the project.
If at any point during the decision-making process you should have questions, please feel
comfortable asking them with high expectations of prompt answers you will understand clearly.
Once your questions have been answered and you are ready to decide to participate in the DNP
project, please complete the attached survey and be involved in the educational session. You are
not surrendering any legal rights by participating in this DNP project.

Why is this project being performed?
The project will aim to develop a clinical plan to implement the use of the Medication
Appropriateness Index by prescribing healthcare providers to evaluate an increase in
deprescribing activity and a decrease the prevalence of polypharmacy in adults aged 62 and
older. This project is designed to educate healthcare providers to utilize a clinical tool, like the
Medication Appropriateness Index, when reviewing medications to determine if any medications
are unnecessary and can be deprescribed. This project is beneficial for healthcare providers and
patients, as polypharmacy is taxing on the healthcare system and on patients’ wellbeing. The
duration of this project will be 9 weeks.
What will you be expected to do if you choose to participate in this project?
First, participants will be asked to participate in one educational session lasting about 30
minutes. At the educational session, the participants will be provided with information, clinical
scenarios, and handouts. The participants will be asked to complete a pre-intervention survey at
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the educational session, and then complete a post-intervention survey at the completion of the
educational session. The participants will be encouraged to provide feedback.
What are the potential risks or disadvantages you may experience if you choose to
participate in this project?
No harm is anticipated for any participants involved in this project. The project has no
input or involvement from any individual in an administration position, and participation is
completely voluntary. No individuals from administration, human resources, or clinical
supervision will be permitted to view any information regarding a participant’s involvement in
this project, feedback given, or survey responses. Furthermore, participants are under no
obligation to change practices after learning in the educational session. No financial
contributions are expected from participants in this project.
Are there any potential benefits from participating in this project?
Participating in this project is a great way to learn more about the Medication
Appropriateness Index clinical tool and the process of deprescribing medications.
How will personal information be kept private and confidential?
While total confidentiality can never be guaranteed, absolute effort will be taken to keep
personal information private during this project. Personal names will not be placed on
documents, rather a randomized ID code will be used on surveys or any other documents.
Surveys will be kept in the clinical facility setting and will not be removed until any and all
identifiable information has been removed. All collected information and data will be completely
discarded upon project completion.
What will happen if you decide to not participate in this project or later decide to end your
participation in this project?
Please remember any participation in this project is completely voluntary. If at any point,
you decide you do not want to begin the project or if you wish to leave the project, you may do
so. Feel free to change your mind about participation at any time. Please understand there is no
point of time before, during, or after the project that you may not choose to stop participating. If
you decide to leave the project, you will not meet any consequences or penalties.
You may retract your consent for data use collected about you prior to your decision to
leave the project, but please do this in writing by sending an email to lgorham@stu.jsu.edu.
Who can you call if you have any questions?
Lori K. Floyd, MSN, CRNP, FNP-C
(256) 657-7037.
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AGREEMENT TO PARTICIPATE
1. Subject Consent:
I have read the entire consent form, or it has been read to me, and I believe
I comprehend what has been discussed. All my questions regarding this
form or this project have been answered or addressed. I agree to
participate in this DNP project.
Subject name: ...........................................................
Subject signature: ..................................................... Date: ....................

2. Signature of Investigator/Individual Obtaining Consent:
To the best of my ability, I have explained, elaborated, and discussed this
DNP project’s complete purpose and content, including all the
information addressed in this consent form. All questions of the DNP
project participants or those of their parent or legally authorized
representative have been concisely and accurately answered.
Investigator/Person Obtaining Consent name: ..............................................
Signature: .................................................................... Date: .......................
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Appendix E
Educational Session Outline: “Polypharmacy and Deprescribing”
Learning Objectives:
1. Discuss the issue of polypharmacy and the important role of deprescribing.
2. Review how, when, and why to use the Medication Appropriateness Index
(MAI) index clinical tool to assist with medication deprescribing.
3. Provide educational resources to participants: copies of MAI clinical tool.
Time in Minutes:

Activity:

2 minutes

Welcome

10 minutes

Pre-intervention Questionnaire and
Background

10 minutes

Present and review MAI. Perform clinical
scenarios

8 minutes

Discussion and Questions

Supplies/equipment needed:
•
•
•

Conference room
Printed materials:
Pencils/Pens
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Appendix F
Medication Appropriateness Index clinical tool and Permission to Use

51

52
Appendix G
DNP Project Timeline
Finalized:

Pre-Design

Summer 2021

Identity gap in
care/clinical
topic.

Design

Create PICOt
question.
Initial Review of
the Literature.
Project
planning/proposal
development.
First
communication
with University
staff regarding
project.

Fall 2021

Begin search for
clinical preceptor.
Revise and
Draft project
complete final
proposal.
PICOt question.
Finalize consent
Creating Title for forms,
DNP Project.
educational
materials, data
Discuss with
collection tables.
University staff
PERC meeting
about project
goals and
and approval.
objectives.
Application for
Assembling DNP IRB approval.
team.

Implementation

Evaluation
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Obtain final
approval for
clinical preceptor
and receive letter
of support.
Draft and create
consent forms,
data collection
tables, participant
educational
materials.
Choose
theoretical
methodology and
nursing theorist.

Spring 2022

Summer 2022

Complete CITI
training.

DNP Project
Implementation.

Collect data and
analyze data.

Collaboration
with clinical
preceptor and
University chair
members.

Begin process
for compilation
of final DNP
manuscript.
Complete DNP
manuscript for
submission.
Poster
presentation.
E-Portfolio
submission.
Participate in
Project
Dissemination
Day.
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Appendix H
DNP Project Budget

PROGRAM EXPENSE

PROJECTED COST
$300.00

ACTUAL COST (Add Later)
$0.00

Start-up costs (copies, charts, displays)

$150.00

$100.00

Capital costs (hardware, equipment)

$100.00

$0.00

Operational costs (heat/electricity)

$50.00

$0.00

Completed copy of Project Manuscript

$200.00

Pending

Total Project Expenses

$800.00

$100.00

Salaries, wages (Admin support, practitioners,
statistics, or writing consultation)
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Appendix I

Deprescribing Review Log
De-identified patient
number

Patient experiencing
polypharmacy and
is a candidate for
deprescribing

Patient is cared for
by healthcare
provider
participating in
project intervention

Were medications
deprescribed* (*see

Yes/No

Yes/No

Yes/No

definition in
manuscript)?
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Appendix J
Pre-intervention Questionnaire

Pre-Intervention Test for Participating Healthcare Providers
Unique ID:
Practice Setting:
Please choose the best and most accurate answer for questions 1-10.

1. Do you find yourself concerned at the number of patients you care for aged 62 years and
older who are experiencing polypharmacy (taking 5 or more medications)?
a. Yes.
b. No.
2. Do you currently use a clinical tool when reviewing a patient’s medication list for
potentially inappropriate or unnecessary medications?
a. Yes.
b. No.
3. Would you be willing to utilize a clinical tool each time you are reviewing a patient’s
medication list to prescribe, deprescribe, or routinely refill medications?
a. Yes.
b. No.
4. Do you feel any solutions or options exist to address the issue of polypharmacy in older
adults?
a. Yes.
b. No.
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5. Do you have personal biases or negative feelings toward the practice of deprescribing
medications for patients experiencing polypharmacy?
a. Yes.
b. No.
6. Have you ever heard of the Medication Appropriateness Index (MAI) clinical tool?
a. Yes.
b. No.
7. Do you know what the primary purpose of the Medication Appropriateness Index (MAI)
clinical tool is?
a. Yes.
b. No.
8. How many questions are included in the Medication Appropriateness Index (MAI)
clinical tool questionnaire?
a. 3 questions.
b. 5 questions.
c. 8 questions.
d. 10 questions.
9.

What information is needed to accurately utilize the Medication Appropriateness Index
(MAI) clinical tool?
a. List of medical problems.
b. List of medications.
c. Both A and B.
d. Neither A or B.

10. After utilizing the Medication Appropriateness Index (MAI) clinical tool, what score
suggests a medication may be unnecessary or inappropriate?
a. 3 or greater.
b. 5 or greater.
c. 7 or greater.
d. 8 or greater.

58
Appendix K
Post-intervention Questionnaire

Post-Intervention Test for Participating Healthcare Providers
Unique ID:
Practice Setting:
Please choose the best and most accurate answer for questions 1-10.

1. Were you surprised by how many medications your patients were taking that could be
considered unnecessary or inappropriate?
a. Yes.
b. No.
c. Somewhat.
d. Unsure.
2. Did you find it convenient to use a clinical tool like the Medication Appropriateness
Index (MAI) to review patient medication lists at each office visit?
a. Yes.
b. No.
c. Somewhat.
d. Unsure.
3. Do you feel utilizing the Medication Appropriateness Index (MAI) clinical tool helps you
review medication lists and deprescribe medications if indicated?
a. Yes.
b. No.
c. Somewhat.
d. Unsure.
4. Did you find the educational sessions and training helpful to understand and implement
the Medication Appropriateness Index (MAI) clinical tool?
a. Yes.
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b. No.
c. Somewhat.
d. Unsure.
5. After the educational session and training, how often did you use the Medication
Appropriateness Index (MAI) clinical tool when reviewing patient medication lists?
a. Always.
b. Usually.
c. Sometimes.
d. Seldom.
e. Never.
6. After the educational session and training, how often did you identify an unnecessary or
inappropriate medication a patient was taking?
a. Always.
b. Usually.
c. Sometimes.
d. Seldom.
e. Never.
7. After the educational session and training, how often did you deprescribe medications for
your patients?
a. Always.
b. Usually.
c. Sometimes.
d. Seldom.
e. Never.
8. After the educational session and training, how often did you agree with the
recommendation to deprescribe a medication based upon the results of the Medication
Appropriateness Index (MAI) clinical tool?
a. Always.
b. Usually.
c. Sometimes.
d. Seldom.
e. Never.
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9. Do you think prescribing healthcare providers are the prime candidates to lead the way
towards deprescribing medications and addressing polypharmacy? Please explain.
a. Yes.
b. No.
10. How prepared do you feel to utilize the Medication Appropriateness Index (MAI) clinical
tool when reviewing patient medication lists to deprescribe unnecessary or inappropriate
medications?
a. Strongly prepared.
b. Somewhat prepared.
c. Neutral.
d. Somewhat unprepared.
e. Strongly unprepared.
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Appendix L
CITI Training Certificate
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Appendix M
University IRB Approval

